HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

CP 154526

structure in first source

Also Known As:

CP 154,526; CP-154,526; CP-154526; butyl-(2,5-dimethyl-7-(2,4,6-trimethylphenyl)-7H-pyrrolo(2,3-d)pyrimidin-4-yl)ethylamine

Networked: 16 relevant articles (1 outcomes, 3 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrroles: 369
      - CP 154526: 16
  - Pyrimidines: 510
    - CP 154526: 16

Experts

1.	Laorden, M L: 2 articles (01/2018 - 02/2014)
2.	Milanés, M V: 2 articles (01/2018 - 02/2014)
3.	Navarro-Zaragoza, Javier: 2 articles (01/2012 - 05/2010)
4.	Million, Mulugeta: 2 articles (04/2008 - 05/2002)
5.	Taché, Yvette: 2 articles (04/2008 - 05/2002)
6.	Almela, P: 1 article (01/2018)
7.	Gómez-Milanés, I: 1 article (01/2018)
8.	Núñez, C: 1 article (01/2018)
9.	Ribeiro Do Couto, B: 1 article (01/2018)
10.	Valero, E: 1 article (01/2018)

Related Diseases

1.	Hyperalgesia 04/01/2008 - "Interestingly, chronically administered CP-154,526 eliminated hyperalgesia and produced responses below baseline at 40 mmHg and 60 mmHg, indicating a hypoalgesic effect of the compound. " 04/01/2008 - "CP-154,526 injected acutely significantly reduced stress-induced visceral hyperalgesia at 40 mmHg but not at 60 mmHg. "
2.	Mood Disorders (Mood Disorder) 03/01/2007 - "The two most characterized V1b and CRF1 antagonists are SSR149415 and CP-154,526, respectively, and the present studies were designed to compare these two compounds in acute animal models of affective disorders. "
3.	Wounds and Injuries (Trauma) 06/01/2004 - "The present studies were undertaken to determine whether a corticotropin releasing factor (CRF)-receptor 1 (R1) antagonist, CP-154,526 (CP) could alter trauma-induced effects on blood glucose levels, insulin action on skeletal muscle, and dexamethasone-induced suppression of endogenous glucocorticoid secretion. "
4.	Ulcer 09/01/2010 - "Results from the antagonist studies showed that CP-154,526 and NBI 27914 either fully or partially reversed the referred ulcer pain with minimal effective doses (MED) equal to 3 and 10 mg/kg, respectively. "
5.	Pain (Aches) 09/01/2010 - "Results from the antagonist studies showed that CP-154,526 and NBI 27914 either fully or partially reversed the referred ulcer pain with minimal effective doses (MED) equal to 3 and 10 mg/kg, respectively. "

Related Drugs and Biologics

1.	Corticotropin-Releasing Hormone Receptors (Corticotropin Releasing-Hormone Receptor)
2.	Insulin (Novolin)
3.	Glucocorticoids
4.	Dexamethasone (Maxidex)
5.	Corticotropin-Releasing Hormone
6.	Blood Glucose (Blood Sugar)
7.	2- methyl- 4- (N- propyl- N- cycloproanemethylamino)- 5- chloro- 6- (2,4,6- trichloranilino)pyrimidine
8.	1- (5- chloro- 1- ((2,4- dimethoxyphenyl)sulfonyl)- 3- (2- methoxyphenyl)- 2- oxo- 2,3- dihydro- 1H- indol- 3- yl)- 4- hydroxy- N,N- dimethyl- 2- pyrrolidinecarboxamide
9.	Morphine (MS Contin)
10.	Messenger RNA (mRNA)